Pfizer, like Moderna, fires back at Alnylam suit over Covid-19 vaccine patents
In the latest development over alleged patent infringement related to Pfizer’s and Moderna’s mRNA vaccines for Covid-19, Pfizer is stepping up to the plate and sharing its side of the story.
RNAi therapeutics giant Alnylam knew before it filed its original suit that Pfizer’s Covid vaccine Comirnaty did not violate Alnylam’s patent, Pfizer wrote in its 37-page response filed late last week in Delaware district court in response to Alnylam’s suit. Alnylam had alleged patent infringement and demanded monetary compensation.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.